Science and Validation

  • Home
  • Science and Validation
Science

Our Science

CanAssist Breast uses a proteomics- based method and a proprietary machine learning-based algorithm to to analyze a patented combination of protein biomarkers from the patient’s tumour to compute the risk of recurrence of cancer.

CanAssist Breast integrates IHC (immunohistochemistry) data and clinical parameters to calculate a risk score that classifies patients as ‘low-risk’ or ‘high-risk’ for breast cancer recurrence over five years. By integrating the tumour biology of the disease with time-tested clinico-pathological parameters we assist physicians in developing optimal treatment plans for cancer patients. The CanAssist Breast test result allows breast cancer patients who are classified as ‘low-risk’ to potentially avoid chemotherapy and its side effects.

  • CanAssist Breast is an immunohistochemistry (IHC)-based novel risk classifier combining five patented biomarkers and three clinico- pathological parameters to calculate risk of cancer recurrence at a site other than breast within five years from diagnosis.
  • The 5 biomarkers chosen play critical roles in cancer recurrence.
  • The machine learning-based techniques used help assess non-linear interactions between the various signaling pathways that play a role in cancer recurrence.

  • CanAssist Breast has been rigorously validated based on various international guidelines. Multiple variables that play a role in test precision have been assessed and the test has been found to be repeatable and reproducible
  • Stringent QC and validation have been done on all IHC protocols used in the CanAssist Breast test performed in the reference laboratory at Bengaluru.
  • Our reference laboratory in Bengaluru is accredited by College of American Pathologists (CAP) and NABL, and participates in various External Quality Assessment Schemes (EQAS).

  • CanAssist Breast has been validated in a retrospective multi-centric clinical study (15+ centres in India, USA & Europe) on close to 2000 patients
  • A significant proportion of the validation cohort were aged 50 or younger, making the test suitable for both young pre-menopausal and older post-menopausal patients.
  • The validation data has been published in several international peer- reviewed journals like Biomarker Insights and Cancer Medicine:
  • Kaplan-Meier survival analysis showed that chemotherapy leads to better results for high-risk patients, but didn’t lead to statistically significant benefit in low-risk patients
  • Cox proportional hazards analysis showed that significant prognostic value was provided by CanAssist Breast compared with other traditional clinicopathological parameters
  • CanAssist Breast provided significant prognostic value, superior to that provided by traditional clinicopathological parameters and tests such as Ki67 and IHC4.

Subscribe
Newsletter

Sign Up Now
Reach Out To Us

+91 96866 96505

Map
Location & Directions

Get Direction